Androgen receptor down regulation by small interference RNA induces cell growth inhibition in androgen sensitive as well as in androgen independent prostate cancer cells

被引:109
作者
Hååg, P [1 ]
Bektic, J [1 ]
Bartsch, G [1 ]
Mocker, H [1 ]
Eder, IE [1 ]
机构
[1] Med Univ Innsbruck, Dept Urol, A-6020 Innsbruck, Austria
基金
奥地利科学基金会;
关键词
androgen receptor; siRNA; androgen independent prostate cancer; gene expression analysis;
D O I
10.1016/j.jsbmb.2005.04.029
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We investigated the effects of androgen receptor (AR) down regulation with a small interference RNA molecule (siRNA_AR(start)) on androgen sensitive LNCaP and androgen independent LNCaPabl prostate cancer cells, the latter representing an in vitro model for the development of therapy resistance in prostate cancer. Although LNCaPabl cells express increased levels of AR in comparison with androgen sensitive LNCaP cells, the protein was significantly down regulated in response to siRNA_AR(start) treatment. This AR down regulation resulted in a marked cell growth inhibition in both cell lines. By contrast, DU-145 prostate cancer cells, which lack AR expression, were not inhibited by the siRNA_AR(start). In consequence to AR down regulation, both cell lines, LNCaP and LNCaPabl, shared a highly similar gene expression profile in terms of major changes in cell cycle regulatory genes. The cell cycle inhibitor p21(Waf1/Cip1) as well as cyclin D1 were significantly up regulated by siRNA_AR(start) treatment, considering a switch in cyclin expression towards cell cycle retardation. Control molecules had moderate effects on cell proliferation and gene expression, respectively. In summary, we found that AR inhibition with siRNA induces cell growth retardation in androgen sensitive as well as in androgen independent prostate cancer cells and thus may represent an interesting approach to combat hormone-refractory prostate cancer. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:251 / 258
页数:8
相关论文
共 26 条
[1]  
BILANGES B, 2005, BIOCH J
[2]   Molecular determinants of resistance to antiandrogen therapy [J].
Chen, CD ;
Welsbie, DS ;
Tran, C ;
Baek, SH ;
Chen, R ;
Vessella, R ;
Rosenfeld, MG ;
Sawyers, CL .
NATURE MEDICINE, 2004, 10 (01) :33-39
[3]   A CONTROLLED TRIAL OF LEUPROLIDE WITH AND WITHOUT FLUTAMIDE IN PROSTATIC-CARCINOMA [J].
CRAWFORD, ED ;
EISENBERGER, MA ;
MCLEOD, DG ;
SPAULDING, JT ;
BENSON, R ;
DORR, FA ;
BLUMENSTEIN, BA ;
DAVIS, MA ;
GOODMAN, PJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (07) :419-424
[4]   Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system [J].
Culig Z. ;
Hoffmann J. ;
Erdel M. ;
Eder I.E. ;
Hobisch A. ;
Hittmair A. ;
Bartsch G. ;
Utermann G. ;
Schneider M.R. ;
Parczyk K. ;
Klocker H. .
British Journal of Cancer, 1999, 81 (2) :242-251
[5]  
CULIG Z, 1994, CANCER RES, V54, P5474
[6]   Inhibition of LNCaP prostate tumor growth in vivo by an antisense oligonucleotide directed against the human androgen receptor [J].
Eder, IE ;
Hoffmann, J ;
Rogatsch, H ;
Schäfer, G ;
Zopf, D ;
Bartsch, G ;
Klocker, H .
CANCER GENE THERAPY, 2002, 9 (02) :117-125
[7]   Inhibition of LNCaP prostate cancer cells by means of androgen receptor antisense oligonucleotides [J].
Eder, IE ;
Culig, Z ;
Ramoner, R ;
Thurnher, M ;
Putz, T ;
Nessler-Menardi, C ;
Tiefenthaler, M ;
Bartsch, G ;
Klocker, H .
CANCER GENE THERAPY, 2000, 7 (07) :997-1007
[8]  
GAO X, 1995, ONCOGENE, V11, P1395
[9]   Specific block of androgen receptor activity by antisense oligonucleotides [J].
Hamy, F ;
Brondani, V ;
Spoerri, R ;
Rigo, S ;
Stamm, C ;
Klimkait, T .
PROSTATE CANCER AND PROSTATIC DISEASES, 2003, 6 (01) :27-33
[10]  
HOBISCH A, 1995, CANCER RES, V55, P3068